Proteomics International Laboratories (ASX:PIQ) issued a notice of termination to Sonic Healthcare USA, the US distributor of its diabetic kidney disease test PromarkerD, effective Tuesday, after not meeting certain milestones to commercialize the test kit, according to a Wednesday filing with the Australian bourse.
Following the termination, the diagnostic firm will now market and sell PromarkerD in the US via licensing deals with service providers, pathology laboratories, and/or direct-to-consumer/patient channels, the filing said.
The company will establish a code-compliant third-party reference laboratory ahead of the test kit's launch, the filing stated.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。